Latest news

• Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention

  The MOVe-AHEAD trial will test whether the drug prevents infection in those living in the same household as someone with confirmed COVID-19. ... If successful, molnupiravir could provide an important additional option towards reducing the burden of

• Roche’s anti-inflammatory drug reduces deaths in hospitalised COVID-19 patients

  Roche’s anti-inflammatory drug tocilizumab, marketed as Actemra/RoActemra, has been found to reduce the risk of death in patients hospitalised with COVID-19, according to a UK study. ... The RECOVERY trial is aiming to identify treatments that may be

• Roche’s Actemra fails in late-stage severe COVID-19 study

  Anti-inflammatory drug unable to improve clinical status of hospitalised patients. Roche’s hopes of repurposing its arthritis med Actmera as a treatment for COVID-19 have fallen flat after the ... Another anti-inflammatory drug, ABX464, is currently

• Abivax doses first patient in phase 2b/3 COVID-19 clinical trial

  A number of pharma companies have been evaluating the efficacy of anti-inflammatory treatments in COVID-19, after overactive inflammatory responses were observed in the lungs of critically and severely ill ... Despite these results, there is still a

• AbbVie suspends Kaletra patent rights as COVID-19 drug trials advance

  This allows countries to purchase generic copies of Kaletra if the drug does suffer a shortage, especially if it is found to be effective at treating COVID-19. ... Other potential drug treatments for COVID-19 include anti-inflammatories, such as